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Abstract
Background
Ecological research suggests that increased access to cannabis may facilitate reductions in
opioid use and harms, and medical cannabis patients describe the substitution of opioids
with cannabis for pain management. However, there is a lack of research using individual-
level data to explore this question. We aimed to investigate the longitudinal association
between frequency of cannabis use and illicit opioid use among people who use drugs
(PWUD) experiencing chronic pain.
Methods and findings
This study included data from people in 2 prospective cohorts of PWUD in Vancouver, Can-
ada, who reported major or persistent pain from June 1, 2014, to December 1, 2017 (n =
1,152). We used descriptive statistics to examine reasons for cannabis use and a multivari-
able generalized linear mixed-effects model to estimate the relationship between daily
(once or more per day) cannabis use and daily illicit opioid use. There were 424 (36.8%)
women in the study, and the median age at baseline was 49.3 years (IQR 42.3–54.9). In
total, 455 (40%) reported daily illicit opioid use, and 410 (36%) reported daily cannabis use
during at least one 6-month follow-up period. The most commonly reported therapeutic rea-
sons for cannabis use were pain (36%), sleep (35%), stress (31%), and nausea (30%). After
adjusting for demographic characteristics, substance use, and health-related factors, daily
cannabis use was associated with significantly lower odds of daily illicit opioid use (adjusted
odds ratio 0.50, 95% CI 0.34–0.74, p < 0.001). Limitations of the study included self-reported
measures of substance use and chronic pain, and a lack of data for cannabis preparations,
dosages, and modes of administration.
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Conclusions
We observed an independent negative association between frequent cannabis use and fre-
quent illicit opioid use among PWUD with chronic pain. These findings provide longitudinal
observational evidence that cannabis may serve as an adjunct to or substitute for illicit opioid
use among PWUD with chronic pain.
Author summary
Why was this study done?
• High numbers of people who use (illicit) drugs (PWUD) experience chronic pain, and
previous research shows that illicit use of opioids (e.g., heroin use, non-prescribed use
of painkillers) is a common pain management strategy in this population.
• Previous research has suggested that some patients might substitute opioids (i.e., pre-
scription painkillers) with cannabis (i.e., marijuana) to treat pain.
• Research into cannabis as a potential substitute for illicit opioids among PWUD is
needed given the high risk of opioid overdose in this population.
• We conducted this study to understand if cannabis use is related to illicit opioid use
among PWUD who report living with chronic pain in Vancouver, Canada, where can-
nabis is abundant and the rate of opioid overdose is at an all-time high.
What did the researchers do and find?
• Using data from 2 large studies of PWUD in Vancouver, Canada, we analyzed informa-
tion from 1,152 PWUD who were interviewed at least once and reported chronic pain
at some point between June 2014 and December 2017.
• We used statistical modelling to estimate the odds of daily opioid use for (1) daily and
(2) occasional users of cannabis relative to non-users of cannabis, holding other factors
(e.g., sex, race, age, use of other drugs, pain severity) equal.
• For participants who reported cannabis use, we also analyzed their responses to a ques-
tion about why they were using cannabis (e.g., for intoxication, for pain relief)
• We found that people who used cannabis every day had about 50% lower odds of using
illicit opioids every day compared to cannabis non-users. People who reported occa-
sional use of cannabis were not more or less likely than non-users to use illicit opioids
on a daily basis. Daily cannabis users were more likely than occasional cannabis users to
report a number of therapeutic uses of cannabis including for pain, nausea, and sleep.
What do these findings mean?
• Although more experimental research (e.g., randomized controlled trial of cannabis
coupled with low-dose opioids to treat chronic pain among PWUD) is needed, these
Cannabis and illicit opioid use among PWUD with pain
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findings suggest that some PWUD with pain might be using cannabis as a strategy to
alleviate pain and/or reduce opioid use.
Introduction
Opioid-related morbidity and mortality continue to rise across Canada and the United States
[1,2]. In many regions, including Vancouver, Canada—where drug overdoses were declared a
public health emergency in 2016—the emergence of synthetic opioids (e.g., fentanyl) in illicit
drug markets has sparked an unprecedented surge in death [3]. The overdose crisis is also the
culmination of shifting opioid usage trends (i.e., from initiating opioids via heroin to initiating
with pharmaceutical opioids [4]) that can be traced back, in part, to the over-prescription of
pharmaceutical opioids for chronic non-cancer pain [5].
Despite this trend of liberal opioid prescribing, certain marginalized populations experienc-
ing high rates of pain, including people who use drugs (PWUD), lack access to adequate pain
management through the healthcare system [6,7]. Under- or untreated pain in this population
can promote higher-risk substance use, as patients may seek illicit opioids (i.e., unregulated
heroin or counterfeit/diverted pharmaceutical opioids) to manage pain [6,7]. In Vancouver,
this practice poses a particularly high risk of accidental overdose, as estimates show that almost
90% of drugs sold as heroin are contaminated with synthetic opioids, such as fentanyl [8].
Another less-examined pain self-management strategy among PWUD is the use of cannabis
[9]. Unlike illicit opioids and illicit stimulants, the cannabis supply (unregulated or regulated)
has not been contaminated with fentanyl, and cannabis is not known to pose a direct risk of
fatal overdose [10]. As a result, cannabis has been embraced by some, including emerging
community-based harm reduction initiatives in Vancouver, as a possible substitute for opioids
in the non-medical management of pain and opioid withdrawal [11]. Further, clinical evidence
supports the use of cannabis or cannabinoid-based medications for the treatment of certain
types of chronic non-cancer pain (e.g., neuropathic pain) [12].
As more jurisdictions across North America introduce legal frameworks for medical or
non-medical cannabis use, ecological studies have provided evidence to suggest that states pro-
viding access to legal cannabis experience population-level reductions in opioid use [13–17],
opioid dependence [18,19], and fatal overdose [19–21]. However, these state-level trends do
not necessarily represent changes within individuals [22], highlighting a critical need to con-
duct individual-level research to better understand whether cannabis use is associated with
reduced use of opioids and risk of opioid-related harms, particularly among individuals with
pain. Of particular interest is a possible opioid-sparing effect of cannabis, whereby a smaller
dose of opioids provides equivalent analgesia to a larger dose when paired with cannabis.
Although this effect has been identified in pre-clinical studies [23], much of the current
research in humans is limited to patient reports of reductions in the use of prescription drugs
(including opioids) as a result of cannabis use [24–34]. However, a recent study among
patients on long-term prescription opioid therapy produced evidence to counter the narrative
that cannabis use leads to meaningful reductions in opioid prescriptions or dose [35]. These
divergent findings confirm an ongoing need to understand this complex issue. To date, there
is a lack of research from real-world settings exploring the opioid-sparing potential of cannabis
among high-risk individuals who may be engaging in frequent illicit opioid use to manage
pain. We therefore sought to examine whether frequency of cannabis use was related to
Cannabis and illicit opioid use among PWUD with pain
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frequency of illicit opioid use among PWUD who report living with chronic pain in Vancou-
ver, Canada, the setting of an ongoing opioid overdose crisis.
Methods
Study sample
Data for this study were derived from 2 ongoing open prospective cohort studies of PWUD in
Vancouver, Canada. The Vancouver Injection Drug Users Study (VIDUS) consists of HIV-
negative people who use injection drugs [36]. The AIDS Care Cohort to evaluate Exposure to
Survival Services (ACCESS) consists of people living with HIV who use drugs [37]. The cur-
rent study, nested within these cohorts, was designed as part of a larger doctoral research proj-
ect (SL) examining cannabis use and access among PWUD in the context of changing
cannabis policy and the ongoing opioid overdose crisis [38]. The analysis plan for this study is
provided in S1 Text. This study is reported as per the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guidelines for cohort studies (S1 Checklist).
Recruitment for the cohort studies has been ongoing since 1996 (VIDUS) and 2005
(ACCESS) through extensive street outreach in various areas across Vancouver’s downtown
core, including the Downtown Eastside (DTES), a low-income neighbourhood with an open
illicit drug market and widespread marginalization and criminalization. To be eligible for
VIDUS, participants must report injecting drugs in the previous 30 days at enrolment. To be
eligible for ACCESS, participants must report using an illicit drug (other than or in addition to
cannabis, which was a controlled substance under Canadian law until October 17, 2018) in the
previous 30 days at enrolment. For both cohorts, HIV serostatus is confirmed through serol-
ogy. Other eligibility requirements include being aged 18 years or older, residing in the Metro
Vancouver Regional District, and providing written informed consent. Aside from HIV-dis-
ease-specific assessments, all study instruments and follow-up procedures are harmonized
between the 2 studies to facilitate combined data analysis and interpretation.
At study enrolment, participants complete an interviewer-administered baseline question-
naire. Every 6 months thereafter, participants are eligible to complete a follow-up question-
naire. The questionnaires elicit information on socio-demographic characteristics, lifetime
(baseline) and past-6-month (baseline, follow-up) patterns of substance use, risk behaviours,
healthcare utilization, social and structural exposures, and other health-related factors. Nurses
collect blood samples for HIV testing (VIDUS) or HIV clinical monitoring (ACCESS) and
hepatitis C virus serology, providing referrals to appropriate healthcare services as needed.
Participants are provided a Can$40 honorarium for their participation at each study visit.
Ethics statement
Ethics approval for this study was granted by the University of British Columbia/Providence
Health Care Research Ethics Board (VIDUS: H14-01396; ACCESS: H05-50233). Written
informed consent was obtained from all study participants.
Measures
To examine the use of illicit opioids and cannabis for possible ad hoc management of pain
among PWUD, we restricted the study sample to individuals experiencing major or persistent
pain. Beginning in follow-up period 17 (i.e., June 2014), the following question was added to
the study questionnaire: “In the last 6 months, have you had any major or persistent pain
(other than minor headaches, sprains, etc.)?” We included all observations from participants
beginning at the first follow-up interview in which they reported chronic pain. For example, a
Cannabis and illicit opioid use among PWUD with pain
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participant who responded “no” to the pain question at follow-up 17 and “yes” at follow-up 18
would be included beginning at follow-up 18. For the purpose of these analyses, this first fol-
low-up period with a pain report is considered the “baseline” interview.
The outcome of interest was frequent use of illicit opioids, defined as reporting daily (once
or more per day) non-medical use of heroin or pharmaceutical opioids (diverted, counterfeit,
or not-as-prescribed use) by injection or non-injection (i.e., smoking, snorting, or oral admin-
istration) in the previous 6 months. This outcome was captured through 4 different multipart
questions based on class of opioid (i.e., heroin and pharmaceutical opioids) and mode of
administration (i.e., injection and non-injection). For example, at each 6-month period, injec-
tion heroin use was assessed through the question: “In the last 6 months, when you were using,
which of the following injecting drugs did you use, and how often did you use them?” Respon-
dents were provided a list of commonly injected drugs, including heroin, and were asked to
estimate their average frequency of injection in the past 6 months according to the following
classifications: <1/month, 1–3/month, 1/week, 2–3/week,�1/day. An identical question for
non-injection drugs assessed the frequency of non-injection heroin use. Pharmaceutical opioid
injection was assessed through the question “In the past 6 months, have you injected any of the
following prescription opioids? If so, how often did you inject them?” Participants were pro-
vided a list of pharmaceutical opioids with corresponding pictures for ease of identification.
The question was repeated for non-injection use of pharmaceutical opioids, and the frequency
categories were identical to those listed above. Using frequency categorizations from these 4
questions, participants who endorsed past-6-month daily injection or non-injection of heroin
or pharmaceutical opioids were coded as “1” for the outcome (i.e., daily illicit opioid use) for
that follow-up period. The main independent variable was cannabis use, captured through the
question “In the last 6 months, have you used marijuana (either medical or non-medical) for
any reason (e.g., to treat a medical condition or for a non-medical reason, like getting high)?”
Those who responded “yes” were also asked to estimate their average past-6-month frequency
of use according to the frequency categories described above. Frequency was further catego-
rized as “daily” (i.e.,�1/day), “occasional” (i.e., <1/month, 1–3/month, 1/week, 2–3/week),
and “none” (no cannabis use; reference category). Sections of the questionnaire used for sam-
ple restriction and main variable building are provided in S2 Text.
We also considered several socio-demographic, substance use, and health-related factors
with the potential to confound the association between cannabis use and illicit opioid use. Sec-
ondary socio-demographic variables included in this analysis were sex (male versus female),
race (white versus other), age (in years), employment (yes versus no), incarceration (yes versus
no), homelessness (yes versus no), and residence in the DTES neighbourhood (yes versus no).
We considered the following substance use patterns: daily crack or cocaine use (yes versus no),
daily methamphetamine use (yes versus no), and daily alcohol consumption (yes versus no).
Health-related factors that were hypothesized to bias the association between cannabis and
opioid use were enrolment in opioid agonist treatment (i.e., methadone or buprenorphine/nal-
oxone; yes versus no), HIV serostatus (HIV-positive versus HIV-negative), prescription for
pain (including prescription opioids; yes versus no), and average past-week pain level (mild–
moderate, severe, or none). The pain variable was self-reported using a pain scale ranging
from 0 (no pain) to 10 (worse possible pain). We used 3 as the cut-point for mild–moderate
pain and 7 as the cut-point for moderate–severe pain. Although there is no universal standard
for pain categorization, these cut-points are common and have been validated in other pain
populations [39]. Due to low cell count for mild pain (scores 1–3), we collapsed this variable
with moderate pain (4–6) to create the mild–moderate category. With the exception of sex and
race, all variables are time-updated and refer to behaviours and exposures in the 6-month
period preceding the interview. All variables except HIV status were derived through self-
Cannabis and illicit opioid use among PWUD with pain
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report. As data for the present study were derived from 2 large cohort studies with broader
objectives of monitoring changing health and substance use patterns in the community, the
study participants and interviewers were blinded to the objective of this particular study.
Statistical analysis
We explored differences in characteristics at baseline according to daily cannabis use status
(versus occasional/none) using chi-squared tests for categorical variables and Wilcoxon rank-
sum tests for continuous variables. Then, we estimated bivariable associations between each
independent variable and the outcome, daily illicit opioid use, using generalized linear mixed-
effects models (GLMMs) with a logit-link function to account for repeated measures within
individuals over time. Next, we built a multivariable GLMM to estimate the adjusted associa-
tion between frequency of cannabis use and illicit opioid use. We used the least absolute
shrinkage and selection operator (LASSO) approach to determine which variables to include
in the multivariable model. This method uses a tuning parameter to penalize the model based
on the absolute value of the magnitude of coefficients (i.e., L1 regularization), shrinking some
coefficients down to 0 (i.e., indicating their removal from the multivariable GLMM). Four-fold
cross-validation was used to determine the optimal value of the tuning parameter. GLMMs
were estimated using complete cases (98.6%–100% of observations for bivariable estimates;
99.0% of observations for multivariable estimates).
In the most recent follow-up period (June 1, 2017, to December 1, 2017), participants who
reported any cannabis use in the previous 6-month period were eligible for the follow-up ques-
tion: “Why did you use it?” Respondents could select multiple options from a list of answers or
offer an alternative reason under “Other”. These data were analyzed descriptively, and differ-
ences between at least daily and less than daily cannabis users were analyzed using a chi-
squared test, or Fisher’s test for small cell counts.
All analyses were performed in RStudio (version 1.1.456; R Foundation for Statistical Com-
puting, Vienna, Austria). All p-values are 2-sided.
Results
Between June 1, 2014, and December 1, 2017, 1,489 participants completed at least 1 study
visit and were considered potentially eligible for these analyses. Of them, 13 participants were
removed due to missing data on the fixed variable for race (n = 9), no response to the pain
question (n = 1), or multiple interviews during a single follow-up period (n = 3). Of the
remaining 1,476 participants, 1,152 (78.0%) reported major or persistent pain during at least
one 6-month follow-up period and were included in this analysis. We considered all observa-
tions from these individuals beginning from the first report of chronic pain, yielding 5,350
study observations, equal to 2,676.5 person-years of observation. There were 424 (36.8%)
female participants in the analytic sample, and the median age at the earliest analytic interview
was 49.3 years (IQR 42.3–54.9).
Over the study period, a total of 410 (35.6%) respondents reported daily and 557 (48.4%)
reported occasional cannabis use throughout at least 1 of the 6-month follow-up periods; 455
(39.5%) reported daily illicit opioid use throughout at least 1 of the 6-month follow-up periods.
At baseline (i.e., the first interview in which chronic pain was reported), 583 (50.6%) partici-
pants were using cannabis either occasionally (n = 322; 28.0%) or daily (n = 261; 22.7%), and
269 (23.4%) were using illicit opioids daily. At baseline, 693 (60.2%) participants self-reported
a lifetime chronic pain diagnosis including bone, mechanical, or compressive pain (n = 347;
50.1%); inflammatory pain (n = 338; 48.8%); neuropathic pain (n = 129; 18.6%); muscle pain
(n = 54; 7.8%); headaches/migraines (n = 41; 5.9%); and other pain (n = 53; 7.6%).
Cannabis and illicit opioid use among PWUD with pain
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Table 1 provides a summary of baseline characteristics of the sample stratified by daily can-
nabis use status (yes versus no). Daily cannabis use at baseline was significantly more common
among men (odds ratio [OR] 1.76, 95% 95% CI 1.30–2.38, p< 0.001) and significantly less
common among those who used illicit opioids daily (OR 0.54, 95% CI 0.37–0.77, p< 0.001).
In bivariable longitudinal analyses (Table 2), daily cannabis use was significantly and nega-
tively associated with daily illicit opioid use (OR 0.60, 95% CI 0.40–0.90, p = 0.013). Other fac-
tors that were negatively associated with daily illicit opioid use in crude analyses were age (OR
0.90 per year older, 95% CI 0.88–0.92, p< 0.001), employment (OR 0.73, 95% CI 0.54–0.99,
p = 0.044), HIV seropositivity (OR 0.41, 95% CI 0.26–0.65, p< 0.001), and having a prescrip-
tion for pain medication (OR 0.67, 95% CI 0.51–0.88, p = 0.004). Significant positive associa-
tions with daily illicit opioid use were detected for DTES residency (OR 2.71, 95% CI 1.99–
3.69, p< 0.001), homelessness (OR 2.95, 95% CI 2.06–4.20, p< 0.001), incarceration (OR
2.00, 95% CI 1.16–3.46, p = 0.013), daily crack or cocaine use (OR 2.77, 95% CI 1.94–3.96, p<
0.001), daily methamphetamine use (OR 6.63, 95% CI 4.31–10.19, p< 0.001), and pain level
(OR 1.33, 95% CI 1.00–1.76, p = 0.046, for mild–moderate pain; OR 1.75, 95% CI 1.28–2.38,
p< 0.001, for severe pain). As shown in Table 2, after adjustment for confounders, the odds of
daily illicit opioid use were significantly lower during periods of daily cannabis use (adjusted
OR 0.50, 95% CI 0.33–0.74, p< 0.001), but not during periods of occasional use (adjusted OR
0.94, 95% CI 0.69–1.27, p = 0.682), relative to periods of no cannabis use.
Of the 414 daily and occasional cannabis users who were interviewed from June 1, 2017, to
December 1, 2017, the most commonly reported motivations for use were for recreation (i.e.,
to get high, socialize; n = 237; 57.2%), to manage pain (n = 148; 35.7%), to aid with sleep
(n = 144; 34.8%), to manage stress (n = 127; 30.7%), to treat nausea or loss of appetite (n = 123;
29.7%), and to reduce the use of other substances/treat addiction or withdrawal (n = 53;
12.8%). Self-reporting pain, insomnia, stress, nausea, mental health, HIV, and spirituality as
reasons for use were all significantly more common for daily cannabis users relative to occa-
sional users (p< 0.05; Fig 1).
Discussion
In this longitudinal study examining patterns of past-6-month frequency of cannabis and illicit
opioid use, we found that the odds of daily illicit opioid use were lower (by about half) among
those who reported daily cannabis use compared to those who reported no cannabis use. How-
ever, we observed no significant association between occasional cannabis use and daily opioid
use, suggesting that there may be an intentional therapeutic element associated with frequent
cannabis use. This is supported by cross-sectional data from the sample in which certain rea-
sons for cannabis use were observed to differ according to cannabis use frequency. Specifically,
daily users reported more therapeutic motivations for cannabis use (including to address pain,
stress, nausea, mental health, or symptoms of HIV or antiretroviral therapy, or to improve
sleep) than occasional users, and non-medical motivations—although common among all
users—were not more likely to be reported by daily users. Together, our findings suggest that
PWUD experiencing pain might be using cannabis as an ad hoc (i.e., improvised, self-directed)
strategy to reduce the frequency of opioid use.
A recent study analyzed longitudinal data from a large US national health survey and found
that cannabis use increases, rather than decreases, the risk of future non-medical prescription
opioid use in the general population [40], providing important evidence to challenge the
hypothesis that increasing access to cannabis facilitates reductions in opioid use. The findings
of our study reveal a contrasting relationship between cannabis use and frequency of opioid
use, possibly due to inherent differences in the sampled populations and their motivations for
Cannabis and illicit opioid use among PWUD with pain
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Table 1. Baseline characteristics of 1,152 people who use drugs with chronic pain, stratified by daily cannabis use.
Characteristic Daily cannabis use Odds ratio (95% CI) p-Value
Yes, n = 261 (22.7%) No, n = 891 (77.3%)
Age, years, median (IQR) 49.0 (42.0–54.5) 49.6 (42.4–48.5) 0.99 (0.98–1.01) 0.391
Sex
Male 190 (72.8) 538 (60.4) 1.76 (1.30–2.38) <0.001
Female 71 (27.2) 353 (39.6) 1.00
Race
White 140 (53.6) 491 (55.1) 0.94 (0.71–1.24) 0.728
Other 121 (46.4) 400 (44.9) 1.00
Employment�
Yes 74 (28.4) 206 (23.1) 1.32 (0.96–1.80) 0.099
No 187 (71.6) 685 (76.9) 1.00
Incarceration�
Yes 15 (5.8) 49 (5.5) 1.05 (0.58–1.91) 0.985
No 244 (94.2) 840 (94.5) 1.00
Downtown Eastside residency�
Yes 141 (54.0) 521 (58.5) 0.83 (0.63–1.10) 0.227
No 120 (46.0) 370 (41.5) 1.00
Homelessness�
Yes 31 (11.9) 148 (16.3) 0.68 (0.45–1.03) 0.066
No 229 (88.1) 742 (83.4) 1.00
Opioid agonist treatment�
Yes 129 (49.4) 470 (53.3) 0.86 (0.65–1.13) 0.304
No 132 (50.6) 412 (46.7) 1.00
Crack/cocaine use�
At least daily 43 (16.5) 142 (16.0) 1.04 (0.72–1.51) 0.916
Less than daily 218 (83.5) 748 (84.0) 1.00
Methamphetamine use�
At least daily 22 (8.4) 102 (11.5) 0.71 (0.44–1.15) 0.202
Less than daily 239 (91.6) 788 (88.6) 1.00
Alcohol use�
At least daily 28 (10.9) 83 (9.4) 1.18 (0.75–1.86) 0.467
Less than daily 229 (89.1) 803 (90.6) 1.00
Illicit opioid use�
At least daily 40 (15.3) 229 (25.7) 0.52 (0.36–0.76) <0.001
Less than daily 221 (84.7) 662 (74.3) 1.00
HIV status
HIV+ 112 (42.9) 408 (45.8) 0.89 (0.67–1.18) 0.452
HIV− 149 (57.1) 483 (54.2) 1.00
Prescription for pain�
Yes 139 (54.1) 413 (47.3) 1.31 (0.99–1.74) 0.064
No 118 (45.9) 461 (52.7) 1.00
Average past-week pain level
Severe 101 (38.5) 330 (37.0) 1.24 (0.72–2.15) 0.525
Mild–moderate 139 (53.4) 474 (53.2) 1.19 (0.69–2.03) 0.618
None 19 (7.3) 77 (8.7) 1.00
Data are n (percent) unless otherwise indicated. Cells for each variable might not add up to the column total, as participants can refuse to answer questions.
�Refers to exposures/behaviours in the previous 6 months.
https://doi.org/10.1371/journal.pmed.1002967.t001
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using cannabis. Within the current study population, poly-substance use is the norm; HIV and
related comorbidities are common; and pain management through prescribed opioids is often
denied, increasing the likelihood of non-medical opioid use for a medical condition [6,9]. Fur-
thermore, our study is largely focused on this relationship in the context of pain (i.e., by exam-
ining individuals with self-reported pain and accounting for intensity of pain). Our findings
align more closely with those of a recent study conducted among HIV-positive patients living
with chronic pain, in which the authors found that patients who reported past-month cannabis
use were significantly less likely to be taking prescribed opioids [41]. While this finding could
Table 2. Unadjusted and adjusted generalized linear mixed-effects models of factors associated with daily illicit opioid use among 1,152 people who use drugs with
chronic pain in Vancouver, Canada.
Characteristic Unadjusted Adjusted
OR (95% CI) p-Value OR (95% CI) p-Value
Cannabis use�
Occasional versus none 1.04 (0.77–1.40) 0.818 0.94 (0.69–1.27) 0.682
Daily versus none 0.60 (0.40–0.90) 0.013 0.50 (0.33–0.74) <0.001
Sex
Male versus female 0.65 (0.41–1.03) 0.067
Age
Per year older 0.90 (0.88–0.92) <0.001 0.92 (0.90–0.94) <0.001
Race
White versus other 0.98 (0.62–1.54) 0.920
Follow-up period
Per 6-month interval 0.99 (0.94–1.05) 0.767
Downtown Eastside residency�
Yes versus no 2.71 (1.99–3.69) <0.001 2.12 (1.54–2.90) <0.001
Homelessness�
Yes versus no 2.95 (2.07–4.21) <0.001 1.91 (1.33–2.73) <0.001
Incarceration�
Yes versus no 2.00 (1.16–3.46) 0.013 1.27 (0.73–2.22) 0.393
Employment�
Yes versus no 0.73 (0.54–0.99) 0.044 0.79 (0.58–1.07) 0.134
Opioid agonist therapy�
Yes versus no 0.90 (0.66–1.22) 0.495
Daily alcohol consumption�
Yes versus no 0.91 (0.57–1.44) 0.673
Daily crack/cocaine use�
Yes versus no 2.77 (1.94–3.96) <0.001 2.74 (1.93–3.90) <0.001
Daily methamphetamine use�
Yes versus no 6.63 (4.31–10.19) <0.001 4.60 (3.02–7.02) <0.001
HIV serostatus
Positive versus negative 0.41 (0.26–0.65) <0.001 0.48 (0.32–0.74) <0.001
Pain prescription�
Yes versus no 0.67 (0.51–0.88) 0.004 0.86 (0.65–1.13) 0.274
Average past-week pain rate
Mild–moderate versus none 1.33 (1.00–1.75) 0.046
Severe versus none 1.75 (1.29–2.37) <0.001
�Refers to exposures/behaviours in the previous 6 months.
https://doi.org/10.1371/journal.pmed.1002967.t002
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have resulted from prescription denial associated with the use of cannabis (or any illicit drug),
we show that daily cannabis users in this setting were slightly more likely to have been pre-
scribed a pain medication at baseline, and adjusting for this factor in a longitudinal multivari-
able model did not negate the significant negative association of frequent cannabis use with
frequent illicit opioid use.
The idea of cannabis as an adjunct to, or substitute for, opioids in the management of
chronic pain has recently earned more serious consideration among some clinicians and scien-
tists. A growing number of studies involving patients who use cannabis to manage pain dem-
onstrate reductions in the use of prescription analgesics alongside favourable pain
management outcomes [24–33]. For example, Boehnke et al. found that chronic pain patients
reported a 64% mean reduction in the use of prescription opioids after initiating cannabis,
alongside a 45% mean increase in self-reported quality of life [29]. Degenhardt et al. found
that, in a cohort of Australian patients on prescribed opioids for chronic pain, those using can-
nabis for pain relief (6% of patients at baseline) reported better analgesia from adjunctive can-
nabis use (70% average pain reduction) than opioid use alone (50% average reduction) [33].
Fig 1. Self-reported reasons for cannabis use among daily (n = 204) and occasional (n = 210) cannabis-using people who use drugs with chronic pain, June–
December 2017. Borders indicate chi-squared or Fisher’s test p< 0.05 (Fisher’s test used for mental health and HIV comparisons).
https://doi.org/10.1371/journal.pmed.1002967.g001
Cannabis and illicit opioid use among PWUD with pain
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002967 November 19, 2019 10 / 16
However, more recent high-quality research has presented findings to question this narrative.
For example, in the 4-year follow-up analysis of the above Australian cohort of pain patients,
no significant temporal associations were observed between cannabis use (occasional or fre-
quent) and a number of outcomes including prescribed opioid dose, pain severity, opioid dis-
continuation, and pain interference [35]. Thus, several other explanations for our current
results, aside from an opioid-sparing effect, are worthy of consideration.
We chose to include individuals with chronic pain regardless of their opioid use status to
avoid exclusion of individuals who may have already ceased illicit opioid use at baseline, as
these individuals may reflect an important subsample of those already engaged in cannabis
substitution. On the other hand, there may be important characteristics, unrelated to pain,
among regular cannabis users in this study that predispose them to engage in less frequent or
no illicit opioid use at the outset. We attempted to measure and control for these factors, but
we cannot rule out the possibility of a spurious connection. For example, individuals in this
cohort who are consuming cannabis daily for therapeutic purposes may simply possess greater
self-efficacy to manage health problems and control their opioid use [42]. However, it is nota-
ble that our finding is in line with a previous study demonstrating that cannabis use correlates
with lower frequency of illicit opioid use among a sample of people who inject drugs in Cali-
fornia, all of whom used illicit opioids [43]. Our study builds on this work by addressing
chronic pain, obtaining detailed information on motivations for cannabis use, and examining
longitudinal patterns.
We observed that daily cannabis users endorsed intentional use of cannabis for a range of
therapeutic purposes that may influence pain and pain interference. After pain, insomnia
(43%) and stress (42%) were the second and third most commonly reported motivations for
therapeutic cannabis use among daily cannabis users. The inability to fall asleep and the inabil-
ity stay asleep are common symptoms of pain-causing conditions [44], and experiencing these
symptoms increases the likelihood of opioid misuse among chronic pain patients [45]. The
relationship between sleep deprivation and pain is thought to be bidirectional [44,46], suggest-
ing that improved sleep management may improve pain outcomes. Similarly, psychological
stress (particularly in developmental years) is a well-established predictor of chronic pain [47]
and is also likely to result from chronic pain. Thus, another possible explanation for our find-
ing is that cannabis use substitutes for certain higher-risk substance use practices in addressing
these pain-associated issues without necessarily addressing the pain itself.
Notably, our findings are consistent with emerging knowledge of the form and function of
the human endocannabinoid and opioid receptor systems. The endogenous cannabinoid sys-
tem, consisting of receptors (cannabinoid type 1 [CB1] and type 2 [CB2]) and modulators (the
endocannabinoids anandamide and 2-arachidonoylglycerol), is involved in key pain process-
ing pathways [48]. The co-localization of endocannabinoid and μ-opioid receptors in brain
and spinal regions involved in antinociception [49], and the modification of one system’s noci-
ceptive response via modulation of the other [50,51], has raised the possibility that the phyto-
cannabinoid tetrahydrocannabinol (THC) might interact synergistically with opioids to
improve pain management. A recent systematic review and meta-analysis found strong evi-
dence of an opioid-sparing effect for cannabis in animal pain models, but little evidence from
9 studies in humans [23]. However, the authors of the meta-analysis identified several impor-
tant limitations potentially preventing these studies in humans from detecting an effect,
including low sample sizes, single doses, sub-therapeutic opioid doses, and lack of placebo
[23]. Since then, Cooper and colleagues have published the results of a double-blind, placebo-
controlled, within-subject study among humans in which they found that pain threshold and
tolerance were improved significantly when a non-analgesic dose of an opioid was co-adminis-
tered with a non-analgesic dose of cannabis [52]. Suggestive of a synergistic effect, these
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findings provide evidence for cannabis’s potential to lower the opioid dose needed to achieve
pain relief [52].
Finally, there is pre-clinical and pilot clinical research to suggest that cannabinoids, particu-
larly cannabidiol (CBD), may play a role in reducing heroin cue-induced anxiety and cravings
[53] and symptoms of withdrawal [54]. Although preliminary, this research supports the idea
that cannabis may also be used to stabilize individuals undergoing opioid withdrawal, as an
adjunct to prescribed opioids to manage opioid use disorder, or as a harm reduction strategy.
Although this evidence extends beyond chronic pain patients, it warrants consideration here
given the shared history of illicit substance use amongst the study sample. It is not clear what
role harm reduction or treatment motivations may have played in the current study since daily
and occasional users did not differ significantly in reporting cannabis use as a strategy to
reduce or treat other substance use. The phenomenon of using cannabis as a tool to reduce fre-
quency of opioid injection has been highlighted through qualitative work in other settings
[55], but further research is needed to determine whether this pattern is widespread enough to
produce an observable effect. Clinical trials that can randomize participants to a cannabis
intervention will be critical for establishing the effectiveness of cannabis both for pain manage-
ment and as an adjunctive therapy for the management of opioid use disorder. Such trials
would begin to shed light on whether the current finding could be causal, what the underlying
mechanisms might be, and how to optimize cannabis-based interventions in clinical or com-
munity settings.
There are several important limitations to this study that should be taken into consider-
ation. First, the cohorts are not random samples of PWUD, limiting the ability to generalize
these findings to the entire community or to other settings. The older median age of the sam-
ple should especially be taken into consideration when interpreting these findings against
those from other settings. Second, as discussed above, we cannot rule out the possibility of
residual confounding. Third, aside from HIV serostatus, we relied on self-report for all vari-
ables, including substance use patterns. Previous work shows PWUD self-report to be reliable
and valid against biochemical verification [56], and we have no reason to suspect that
responses about the outcome would differ by cannabis use status, especially since this study
was nested within a much larger cohort study on general substance use and health patterns
within the community. Major or persistent pain, which qualified respondents for inclusion in
this study, was also self-reported. Our definition for chronic pain is likely to be more sensitive
than other assessments of chronic pain (e.g., clinical diagnoses or assessments that capture
length of time with pain). Although more than half (60%) of the sample reported ever having
been diagnosed with a pain condition, it is possible that some of the included respondents
would not have met criteria for a formal chronic pain diagnosis. Finally, we did not collect
information on the type of cannabis, mode of administration, cannabinoid content (e.g., per-
cent THC:percent CBD), or dose during the study period. Future research will need to address
these gaps to provide a more detailed picture of the instrumental use of cannabis for pain and
other health concerns among PWUD.
Conclusions
In conclusion, we found evidence to suggest that frequent use of cannabis may serve as an
adjunct to or substitute for illicit opioid use among PWUD with chronic pain in Vancouver.
The findings of this study have implications for healthcare and harm reduction service provid-
ers. In chronic pain patients with complex socio-structural and substance use backgrounds,
cannabis may be used as a means of treating health problems or reducing substance-related
harm. In the context of the current opioid crisis and the recent rollout of a national regulatory
Cannabis and illicit opioid use among PWUD with pain
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002967 November 19, 2019 12 / 16
framework for cannabis use in Canada, frequent use of cannabis among PWUD with pain
may play an important role in preventing or substituting frequent illicit opioid use. PWUD
describe a wide range of motivations for cannabis use, some of which may have stronger impli-
cations in the treatment of pain and opioid use disorder. Patient–physician discussions of
these motivations may aid in the development of a treatment plan that minimizes the likeli-
hood of high-risk pain management strategies, yet there remains a clear need for further train-
ing and guidance specific to medical cannabis use for pain management [57].
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